We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App

BioMérieux Spotlights Diagnostic Solutions in Use of Antibiotics

By LabMedica International staff writers
Posted on 07 Aug 2019
Print article
Image: The Bact/Alert Virtuo diagnostic solution (Photo courtesy of BioMérieux).
Image: The Bact/Alert Virtuo diagnostic solution (Photo courtesy of BioMérieux).
BioMérieux (Marcy-l'Étoile, France) showcased its unique and comprehensive range of diagnostic solutions that support the responsible use of antibiotics to improve patient care at AACC 2019. Among its diagnostic solutions highlighted at the tradeshow was Bact/Alert Virtuo, which along with bioMérieux’s Bact/Alert Virtuo blood culture system and Bact/Alert Fan Plus media, provides fast and actionable results for better antimicrobial stewardship.

BioMérieux showcased its Vitek 2 automated system consisting of instruments, software, and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. The company also highlighted its Advanced Expert System (AES), which analyzes MIC patterns and detects resistance phenotypes for most organisms tested. Also showcased at the event was bioMérieux’s Vitek MS mass spectrometry microbial identification system that uses MALDI-TOF technology and contains a comprehensive database FDA 510(k) cleared for 401 organisms with 1,316 total organisms to provide highly-accurate identifications.

At AACC 2019, bioMérieux showcased the Vidas 3 fully automated benchtop immunoassay system based on the proven ELFA technology, for specialty testing at the fingertips. Vidas 3 features Vidas B•R•A•H•M•S PCT, which is FDA-cleared to aid in decision-making on antibiotic therapy for patients with sepsis and patients with suspected or confirmed lower respiratory tract infections (LRTI). Other solutions showcased at the event included the Nephrocheck test to gauge the risk of acute kidney injury (AKI) and intervene before damage occurs and the MYLA software which provides a real-time, control-tower overview for blood culture, identification, and antimicrobial susceptibility with flexible, easy-to-generate reports, offering flexible data insights to help drive proactive antimicrobial stewardship and optimal patient management.

BioMérieux also highlighted its AGILIST advanced analytic platform which securely connects and integrates siloed systems into a single source focused on operational efficiency, antimicrobial stewardship and surveillance, analyzing data in real-time, addressing problems, providing reliable information, and improving communications among key stakeholders. Additionally, bioMérieux showcased the PhenoMATRIX for WASPLab that allows labs to take their automated processes to the next level by utilizing artificial intelligence and interpretative algorithms for sample interpretation and automated sorting. PhenoMATRIX evaluates growth on a media plate through user-defined custom rules, allowing staff to spend less time reading plates and focus on those that are positive.

Gold Supplier
Quantitative Immunoassay Analyzer
Lactose Intolerance Test
Lactose Intolerance LCT Kit
Glucose & Lactate Measuremen Device
Zika Virus ELISA Test

Print article


Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.